Zimmer Biomet (NYSE:ZBH) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Zimmer Biomet (NYSE:ZBH) had its target price increased by investment analysts at Canaccord Genuity Group from $83.00 to $100.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the medical equipment provider’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 3.59% from the stock’s current price.

ZBH has been the subject of several other reports. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup dropped their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. JPMorgan Chase & Co. cut their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Robert W. Baird set a $104.00 price target on Zimmer Biomet in a report on Thursday. Finally, UBS Group restated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $96.54 on Monday. The firm’s fifty day moving average price is $90.17 and its 200 day moving average price is $90.15. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a market cap of $18.41 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 3.07 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet will post 8.53 EPS for the current year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Main Management ETF Advisors LLC increased its position in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after buying an additional 112 shares in the last quarter. Citizens National Bank Trust Department raised its stake in Zimmer Biomet by 17.6% in the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 141 shares during the last quarter. LOM Asset Management Ltd raised its stake in Zimmer Biomet by 21.5% in the 4th quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 147 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in Zimmer Biomet by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after purchasing an additional 152 shares in the last quarter. Finally, TD Private Client Wealth LLC lifted its holdings in Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after purchasing an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.